Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review – Part I: Antidepressants

Abstract

Sexual dysfunction is a potential side effect of antidepressant drugs: this article presents a critical review of the current literature. Although many studies have been published on this subject, only some have used a validated sexual function rating scale and most lacked either a baseline or placebo control or both. In addition, many of the studies on sexual dysfunction associated with antidepressants are limited by other methodological flaws. However, there is consistent evidence to suggest that antidepressant medication adversely affects one or more of the 3 phases of sexual response (desire, arousal and orgasm). Antidepressants with strong serotonergic properties have the highest rate of sexual side effects. Clinicians must be aware of drug-induced sexual dysfunction, since its presence can have important consequences on clinical management and compliance.

Key words

antidepressant drugs - sexual dysfunction - sexual side effects - treatment-emergent sexual dysfunction

• References

• 1 Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105
• 2 Baldwin DS. Depression and sexual dysfunction. Br Med Bull 2001; 57: 81-99
• 3 Balon R. Depression, antidepressants, and human sexuality. Prim Psychiatry 2007; 14: (42-44) 47-50
• 4 Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry 2006; 163: 1504-1509
• 5 Balon R, Yeragani VK, Pohl R et al. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209-212
• 6 Clayton AH. Antidepressant-associated sexual dysfunction: a potentially avoidable therapeutic challenge. Prim Psychiatry 2003; 10: 55-61
• 7 Cohen S, Kühn KU, Sträter B et al. Adverse side-effect on sexual function caused by psychotropic drugs and psychotropic substances. Nervenarzt 2010; 81: 1129-1139
• 8 Davidson JRT. Sexual dysfunction and antidepressant. Depression 1995; 2: 233-240
• 9 Waldinger MD, Olivier B. Selective serotonin reuptake inhibitor-induced sexual dysfunction: clinical and research considerations. Int Clin Psychoparmacol 1998; 13: S27-S33
• 10 Werneke U, Northey S, Bhugra D. Antidepressant and sexual dysfunction. Acta Psychiatr Scand 2006; 114: 384-397
• 11 Williams VSL, Edin HM, Hogue SL et al. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol 2010; 24: 489-496
• 12 Haberfellner EM. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. Pharmacopsychiatry 2007; 40: 173-182
• 13 La Torre A. Impotenze sessuali indotte da psicofarmaci. In: Rifelli G, Rifelli G. eds. Impotenza maschile, femminile, di coppia. Roma: Scione; 2010. 381-399
• 14 Taylor MJ. Strategies for managing antidepressant-induced sexual dysfunction: a review. Curr Psychiatry Rep 2006; 8: 431-436
• 15 Boyarsky BK, Hirschfeld RM. The management of medication-induced sexual dysfunction. Essent Psychopharmacol 2000; 3: 39-58
• 16 Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. third edition. New York: Cambridge University Press; 2008
• 17 Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care 2002; 38: 111-116
• 18 Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006; 91: 27-32
• 19 Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychoparmacol 2009; 29: 259-266
• 20 Serretti A, Chiesa A. Antidepressivi e disfunzione sessuale: epidemiologia, meccanismi e strategie di trattamento. Giornale Italiano di Psicopatologia 2010; 16: 104-113
• 21 Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002; 69: 119-140
• 22 Rosen RC. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003; 64: 5-10
• 23 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67-85
• 24 Sthal SM. The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry 2001; 62: 80-81
• 25 Sthal SM. The psychopharmacology of sex, Part 2: Effects of drugs on the 3 phases of the human sexual response. J Clin Psychiatry 2001; 62: 147-148
• 26 Montejo-Gonzales AI, Llorca G, Izquierdo JA et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23: 176-194
• 27 Corona G, Ricca V, Bandini E et al. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med 2009; 6: 1259-1269
• 28 Gitlin M. Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother 2003; 4: 2259-2269
• 29 Kennedy SH, Fulton KA, Bagby RM et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006; 51: 234-242
• 30 Ben Zion IZ, Tessler R, Cohen L et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry 2006; 11: 782-786
• 31 Bishop JR, Ellingrod VL, Akroush M et al. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol 2009; 24: 207-215
• 32 Bishop JR, Moline J, Ellingrod VL et al. Serotonin 2A-1438 G/A and G-Protein Beta 3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side effects. Neuropsychopharmacology 2006; 31: 2281-2288
• 33 Zourková A, Cesková E, Hadasová E et al. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007; 33: 343-355
• 34 Zourková A, Hadasová E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J Sex Marital Ther 2002; 28: 451-461
• 35 Harrison WM, Rabkin JG, Ehrhardt AA et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986; 6: 144-149
• 36 Hekimian LJ, Freidhoff AJ, Deever E. A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. J Clin Psychiatry 1978; 39: 633-637
• 37 Karp JF, Frank E, Ritenour A et al. Imipramine and sexual dysfunction during the long term treatment of recurrent depression. Neuropsychopharmacology 1994; 11: 21-27
• 38 Monteiro WO, Noshirvani HF, Marks IM et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987; 151: 107-112
• 39 Althof SE. Pharmacological treatment of rapid ejaculation. Psychiatr Clin North Am 1995; 18: 85-94
• 40 Althof SE, Levine SB, Corty EW et al. A double-bind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995; 56: 402-407
• 41 Althof SE, Resnick K, Levine S et al. Early experience with clomipramine for rapid ejaculation. J Urol 1995; 153: 474A
• 42 Girgis SM, El-Haggar S, El-Hermouzy S. A double-bind trial of clomipramine in premature ejaculation. Andrologia 1982; 14: 364-368
• 43 Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urology 1998; 159: 425-427
• 44 La Torre A. Il trattamento psicofarmacologico dell’eiaculazione precoce: analisi della letteratura. Rivista di Sessuologia 1999; 23: 379-401
• 45 Rowland DL, Tai WL, Brummett K et al. Predicting responsiveness to the tretment of rapid ejaculation with 25 mg clomipramine as needed. Int J Impot Res 2004; 16: 354-357
• 46 Segraves RT, Saran A, Segraves K et al. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther 1993; 19: 198-200
• 47 Strassberg DS, De Gouveia Brazao CA, Rowland DL et al. Clomipramine in the treatment of rapid (premature) ejaculation. J Sex Marital Ther 1999; 25: 89-101
• 48 Waldinger MD, Zwindermann AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004; 46: 510-516
• 49 Kulik FA, Wilbu R. Case report of painful ejaculation as a side effect of amoxapine. Am J Psychiatry 1982; 139: 234-235
• 50 Noyes R, Garvey MJ, Cook BL et al. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50: 163-169
• 51 Herman JB, Brotman AW, Pollack MH et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51: 25-27
• 52 Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119-122
• 53 Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1993; 54: 71
• 54 Zajecka J, Fawcett J, Schaff M et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991; 52: 66-68
• 55 Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 1997; 33: 755-760
• 56 Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001; 62: 10-21
• 57 Gregorian RS, Golden KA, Bahce A et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36: 1557-1589
• 58 Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357-366
• 59 Devane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995; 10: 185-193
• 60 Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002; 63: 13-16
• 61 Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62: 22-34
• 62 Williams VSL, Baldwin DS, Hogue SL et al. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 european countries: a cross-sectional patient survey. J Clin Psychiatry 2006; 67: 204-210
• 63 Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009; 29: 157-164
• 64 Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 2009; 43: 795-808
• 65 Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31: 257-262
• 66 Reimherr FW, Chuinard G, Cohn CK et al. Antidepressant efficacy of sertraline: a doubleblind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51: 18-27
• 67 Piazza LA, Markowitz JC, Kocsis JH et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry 1997; 154: 1757-1759
• 68 Smith DM, Levitte SS. Association of fluoxetine and return of sexual potency in three elderly man. J Clin Psychiatry 1999; 54: 317-319
• 69 Benazzi F. Involuntary sperm emission with fluoxetine. Can J Psychiatry 1995; 40: 431
• 70 Kaplan PM. The use of serotoninergic uptake inhibitors in the treatment of premature ejaculation. J Sex Marital Ther 1994; 20: 321-324
• 71 Waldinger MD. Lifelong premature ejaculation: from authorithy-based to evidence-based medicine. BJU Int 2004; 93: 201-207
• 72 Waldinger MD, Zwindermann AH, Schweitzer DH et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369-381
• 73 Jannini EA, McMahon CG, Marcel D, et al. eds. Premature Ejaculation. From Etiology to Diagnosis and Treatment. 2013. Springer-Verlag; Italia:
• 74 Clayton AH, Zajecka J, Ferguson JM et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 2003; 18: 151-156
• 75 Langworth S, Bodlund O, Agren S. Efficacy and tolerability of reboxetine compared with citalopram. J Clin Psychopharmacol 2006; 26: 121-127
• 76 Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11: S33-S37
• 77 Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006; 20: 91-96
• 78 Kennedy SH, Eisfeld BS, Dickens SE et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61: 276-281
• 79 Altindag A. A case series of increased libido and spontaneous orgasm associated with venlafaxine treatment. Progress Neuropsychopharmacol Biol Psychiatry 2008; 32: 895-896
• 80 Michael A, Owen A. Venlafaxine-induced increased libido and spontaneous erections. Br J Psychiatry 1997; 170: 193
• 81 Kilic S, Ergin H, Baydinc YC. Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. Int J Androl 2005; 28: 47-52
• 82 Zahariou A, Papaioannou P, Karagiannis G. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007; 39: 115-118
• 83 Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004; 65: 46-52
• 84 Clayton A, Kornstein S, Prakash A et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4: 917-929
• 85 Delgado PL, Brannan SK, Mallinckrodt CH et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66: 686-692
• 86 Nelson JC, Pritchett YL, Martynorv O et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006; 8: 212-219
• 87 Behnke K, Sogaard J, Martin S et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003; 23: 358-364
• 88 Boyarsky BK, Haque W, Rouleau MR et al. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999; 9: 175-179
• 89 Labbate LA. Psychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med 2008; 29: 107-130
• 90 Saiz-Ruiz J, Montes JM, Ibanez A et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol 2005; 20 () 435-440
• 91 Gelenberg AJ, McGahuey C, Laukes C et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61 () 356-369
• 92 Versiani M, Moreno R, Ramakers-van Moorsel CJA et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19: 137-146
• 93 Wade A, Crawford GM, Angus M et al. A randomised, double-blind, 24-weekstudy comparing the efficacy and tolerability of mirtazepine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003; 18: 133-141
• 94 Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment. J Clin Psychiatry 1999; 60: 260-261
• 95 Modell JG, Katholi CR, Modell JD et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61: 476-487
• 96 Dobkin RD, Menza M, Marin H et al. Bupropion improves sexual functioning in depressed minority women: an open-label switch study. J Clin Psychopharmacol 2006; 26: 21-26
• 97 Gardner EA, Johnston JA. Bupropion: an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985; 5: 24-29
• 98 Safarinejad MR, Hosseini SY, Asgari MA et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int 2010; 106: 832-839
• 99 Segraves RT, Croft H, Kavoussi R et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in non depressed women. J Sex Marital Ther 2001; 27: 303-316
• 100 Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987; 13: 239-252
• 101 Gitlin MJ, Suri R, Altshuler L et al. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther 2002; 28: 131-138
• 102 Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 1994; 12: 109-112
• 103 Safarinejad MR. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. BJU Int 2010; 106: 840-847
• 104 Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J Psychopharmacol 2011; 25: 370-378
• 105 Thase ME, Haight BR, Richard N et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66: 974-981
• 106 Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008; 22: 613-617
• 107 Dhillon S, Yang LPH, Curran MP. Bupropion. A review of its use in the management of major depressive disorder. Drugs 2008; 68: 653-689
• 108 Calandra C, Terranova F, Loiacono P et al. Bupropione nel trattamento del disturbo depressivo maggiore: confronto con paroxetina. Giornale Italiano di Psicopatologia 2010; 16: 128-133
• 109 Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67: 736-746
• 110 Coleman C, King B, Bolden-Watson C et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Therapeutics 2001; 23: 1040-1058
• 111 Walker PW, Cole JO, Gardner EA et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54: 459-465
• 112 Croft H, Settle E, Houser T et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21: 643-658
• 113 Coleman CC, Cunningham LA, Foster VG et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999; 11: 205-215
• 114 Thase ME, Clayton AH, Haight BR et al. A double-blind comparison between bupropion XL and venlafaxine XR. Sexual functioning, antidepressant efficacy and tolerability. J Clin Psychoparmacol 2006; 26: 482-488
• 115 Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004; 3: 457-470
• 116 Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002; 47: 174-180
• 117 Philipp M, Kohnen R, Benkert O. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993; 7: 149-153
• 118 Ramasubbu R. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression. J Psychiatry Neurosci 1999; 24: 45-50
• 119 Yeragani VK, Gershon S. Priapism related to phenelzine therapy. N Eng J Med 1987; 317: 117-118
• 120 Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther 1996; 22: 209-217
• 121 Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry 2008; 10: 25-30
• 122 Feiger A, Kiev A, Shrivastava RK et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57: 53-62
• 123 Ferguson JM, Shrivastava RK, Stahl SM et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001; 62: 24-29
• 124 Waldinger MD, Zwindermann AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline and nafazodone. J Clin Psychopharmacol 2001; 21: 293-297
• 125 Micheal A, Ramana R. Nefazodone-induced spontaneous ejaculation. Br J Psychiatry 1996; 169: 672-673
• 126 Gartrell N. Increased libido in women receiving trazodone. Am J Psychiatry 1986; 143: 781-782
• 127 Sullivan G. Increased libido in three man treated with trazodone. J Clin Psychiatry 1988; 49: 202-203
• 128 Warner MD, Peabody CA, Whiteford HA et al. Trazodone and priapism. J Clin Psychiatry 1987; 48: 244-245
• 129 Kennedy SH. Favorable sexual profile of agomelatine in depressed patients. Eur Neuropsychopharmacol 2006; 16: S 319
• 130 Kennedy SH, Rizvi S, Fulton K et al. A Double-blind comparison of sexual functioning, antidepressant efficacy and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-333
• 131 Montejo AL, Prieto N, Terleira A et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010; 1: 111-120
• 132 Atmaca M, Kuloglu M, Tezcan E et al. Switching to tianeptine in patients with antidepressant induced sexual dysfunction. Hum Psychopharmacol Clin Exp 2003; 18: 277-280
• 133 Dording CM, Mischoulon D, Shyu I et al. SAMe and sexual functioning. Eur Psychiatry 2012; 27: 391-476
• 134 Fabre LF, Clayton AH, Smith LC et al. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. J Sex Med 2012; 9: 821-829
• 135 Clayton AH, Kennedy SH, Edwards JB et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 2012; published online: 2012 DEC 6,
• 136 Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888-893
• 137 National Institutes of Health (NIH) . NIH Consensus development panel on impotence. JAMA. 1993. 270. 83-90
• 138 Balon R. The DSM criteria of sexual dysfunction: need for a change. J Sex Marital Ther 2008; 34: 186-197
• 139 Balon R, Segraves RT, Clayton A. Issues for DSM-V: sexual dysfunction, disorder, or variation along normal distribution: toward rethinking DSM criteria of sexual dysfunctions. Am J Psychiatry 2007; 164: 198-200
• 140 American Psychiatric Association . DSM 5 Devolepment. Available on line at . http://www.dsm5.org/Pages/Default.aspx (latest access on 2010 September 14)
• 141 Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19: 114-124
• 142 Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26: 130-140
• 143 Serretti A, Chiesa A. Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 2011; 89: 142-147
• 144 Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunction. Adv Psychosom Med 2008; 29: 89-106
• 145 Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13: S1-S4
• 146 Chen KC, Yang YK, Lee IH et al. Sexual dysfunction and physicians’ perception in medicated patients with major depression in Taiwan. Depress Anxiety 2008; 25: E56-E62
• 147 Cohen S, Kühn K-U, Bender S et al. Sexual impairment in psychiatric inpatients: focus on depression. Pharmacopsychiatry 2007; 40: 58-63
• 148 Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther 2008; 34: 353-365
• 149 Rudkin L, Taylor MJ, Hawton KKE. Strategies for managing sexual dysfunction induced by antidepressant medication (protocol). The Cochrane Database of Systematic Reviews 2002; Issue 4. Art. No.: CD003382.
• 150 Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006; 67: 33-37
• 151 Michelson D, Bancroft J, Targum S et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000; 157: 239-243
• 152 Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol 2004; 19: 545-548
• 153 Dording CM, Fisher L, Papakostas G et al. A double-blind, randomized, pilot dose-finding study of maca root (L.Meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapeutics 2008; 14: 182-191
• 154 Modabbernia A, Sohrabi H, Nasehi AA et al. Effect of saffron on fluoxe­tine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology 2012; 223: 381-388
• 155 Clayton AH, Warnock JK, Kornstein SG et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65: 62-67
• 156 Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013 http://dx.doi.org/10.1155/2013/256841
• 157 Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 2001; 62: 35-43